Skip to main content
Jenkem Technology Co., Ltd. logo

Jenkem Technology Co., Ltd. — Investor Relations & Filings

Ticker · 688356 ISIN · CNE1000043K9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-04-29 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688356

About Jenkem Technology Co., Ltd.

https://www.jenkem.com/

Jenkem Technology Co., Ltd. specializes in the research, development, and large-scale manufacturing of high-purity polyethylene glycol (PEG) derivatives and related polymers. The company provides a comprehensive portfolio of PEG products, including monodisperse and polydisperse PEG linkers, multi-arm PEGs, and functionalized derivatives such as NHS esters, maleimides, and amines. These materials are primarily utilized in advanced drug delivery systems, PEGylation of proteins and peptides, and the development of medical devices and hydrogels. In addition to its core PEG offerings, the company produces biodegradable polymers, including PLA, PLGA, and PCL. Jenkem Technology supports the global biotechnology and pharmaceutical sectors through custom synthesis and high-quality manufacturing processes designed to meet rigorous technical specifications for therapeutic and diagnostic applications.

Recent filings

Filing Released Lang Actions
Corporate Value and Return Enhancement Action Plan 2024
Investor Presentation Classification · 95% confidence The document is titled 'CORPORATE VALUE AND RETURN ENHANCEMENT ACTION PLAN' and is dated April 2024. It outlines strategic plans for technology innovation, product development, market development, talent cultivation, and organizational development. It also discusses profit distribution policies, dividend objectives, and cash dividend ratios. The content is focused on corporate strategy, governance, and investor return enhancement rather than presenting financial statements or earnings data. There is no indication that this is an official annual or quarterly financial report, audit report, or earnings release. The document is comprehensive and detailed, not a brief announcement or a certification. It is a strategic plan document aimed at investors and stakeholders outlining the company's plans to enhance corporate value and investor returns. This aligns best with an Investor Presentation (IP) as it focuses on financials, strategy, and market position for investors.
2024-04-29 Chinese
2024年度提质增效重回报行动方案
Investor Presentation Classification · 95% confidence The document is titled as an "行动方案" (Action Plan) for 2024 by Beijing Jenkem Technology Co., Ltd., focusing on improving quality, efficiency, and investor returns. It details the company's business focus, R&D plans, market development, talent development, governance improvements, profit distribution policies, investor communication, share repurchase plans, and governance enhancements. The document is comprehensive but does not contain actual financial statements or quarterly/yearly financial results. It is a strategic and operational plan document aimed at investors and stakeholders outlining the company's initiatives and governance improvements for the year. It also includes a detailed share repurchase plan but does not serve as a formal announcement of a share buyback transaction. The document is not an earnings release, annual report, interim report, or regulatory filing. It is a detailed investor-oriented plan and presentation of company strategy and governance for the year 2024. Therefore, the best fitting category is Investor Presentation (IP). The document length (8216 characters) supports it being a full presentation rather than a brief announcement or regulatory filing.
2024-04-29 Chinese
关于自愿披露注射用交联透明质酸钠凝胶注册申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Jiankai Technology Co., Ltd. regarding the acceptance of a registration application for a medical device product by the National Medical Products Administration's Medical Device Technical Review Center. It details the product, clinical trials, and risk warnings. The document is short (1205 characters) and serves as a regulatory announcement about the acceptance of a registration application, not a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. It is an official regulatory announcement about a product registration acceptance, fitting best under Regulatory Filings (RNS).
2024-04-08 Chinese
关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Beijing Jiankai Technology Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It includes details such as the repurchase plan approval date, repurchase period, amount, purpose, cumulative shares repurchased, and prices. The document references compliance with relevant regulations and the company's obligation to disclose repurchase progress monthly. The content focuses on the update of the company's share buyback activity rather than financial results, management changes, or other report types. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-04-01 Chinese
关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Beijing Jiankai Technology Co., Ltd. regarding the company's first share repurchase through centralized bidding on the Shanghai Stock Exchange. It details the number of shares repurchased, prices, total funds used, and references the board meeting approving the repurchase plan. The document is focused on the company's share buyback activity and does not contain financial statements or comprehensive financial data. It is not a report but an announcement of a share repurchase transaction.
2024-03-26 Chinese
2023年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023年度业绩快报公告" which translates to "2023 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2023, including revenue, profit, earnings per share, and asset information. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the company's 2023 annual report. The document is relatively short (2456 characters) and serves as a quick earnings update rather than a full annual report. It does not contain full financial statements or detailed analysis typical of a 10-K or full Annual Report. This type of document is best classified as an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. FY 2023
2024-02-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.